Overview
Forward Pharma A/S is a Danish biopharmaceutical company that commenced development in 2005 of FP187, a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The Company owns a significant intellectual property (IP) portfolio related to DMF formulations. The Company granted to Biogen an irrevocable license to all of its IP through the recent License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017. The Company has the opportunity to receive royalties from Biogen on sales of Tecfidera® or other DMF products for MS, dependent on, among other things, successfully appealing the U.S. interference and a favorable outcome in Europe with respect to the EP2801355 opposition proceeding.
| Date | Title | | | 07/18/17 | Forward Pharma announces planned distribution of EUR 19.45 per share to Shareholders| COPENHAGEN, Denmark, July 18, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“the Company” or “Forward”) today announced plans to return EUR 19.45 per share amounting to a total of EUR 917.7 million to its shareholders through a capital reduction. This decision is based on a careful evaluation of the most appropriate capital allocation strategy after receipt of the non-refundable USD 1.25 billion cash fee from Biogen. The capital reduction aligns the amount of working capital with t... |
|  | | 06/14/17 | Forward Pharma CEO to Present at the JMP Securities 2017 Life Sciences Conference on June 20, 2017| COPENHAGEN, Denmark, June 14, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen, the Company’s Chief Executive Officer, will present at the JMP Securities 2017 Life Sciences Conference being held June 20-21, 2017 in New York, NY. Dr. Svendsen will present on Tuesday, June 20, at 3:30 PM ET and host one-on-one meetings before and after the presentation.
Investors and other interested parties may access a live audio webcast of ou... |
| | | 06/02/17 | Forward Pharma CEO to Present at the Jefferies 2017 Global Healthcare Conference on June 6, 2017| COPENHAGEN, Denmark, June 02, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen, the Company’s Chief Executive Officer, will present at the Jefferies 2017 Global Healthcare Conference being held June 6-9, 2017 in New York, NY. Dr. Svendsen will present on Tuesday, June 6, at 3:00 PM ET and host one-on-one meetings before and after the presentation.
Investors and other interested parties may access a live audio webcast of our ... |
| | | 05/31/17 | Forward Pharma Appeals the Initial Decision in the U.S. Patent Interference to the Federal Circuit| COPENHAGEN, Denmark, May 31, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”) today announced the filing of the notice of appeal of the PTAB decision that ended the interference proceeding between the Forward 11/576,871 patent application (the “’871 application”) and an issued Biogen patent. The appeal was filed to the U.S. Court of Appeals for the Federal Circuit (“Federal Circuit”) and seeks to have the decision overturned and the interference reinstated.... |
| |
|
 |
| There are currently no events scheduled. |
Receive E-mail Alerts |
| Sign up to receive e-mail alerts whenever Forward Pharma A/S posts new information to the site. Just enter your e-mail address and click Submit. |
